Direct oral anticoagulants and the risk of adverse clinical outcomes among patients with different body weight categories: a large hospital-based study

Keyphrases

• Hospital-based Study 100%
• Adverse Clinical Outcomes 100%
• Direct Oral Anticoagulants 100%
• Body Weight Category 100%
• Large Hospital 100%
• Morbid Obesity 44%
• All-cause Mortality 22%
• Normal Weight 22%
• Apixaban 22%
• Kaplan-Meier 22%
• Ischemic Stroke 22%
• High Body Weight 22%
• Low Dose Rate 11%
• Clinically Significant 11%
• Regression Analysis 11%
• Obesity 11%
• Clinical Outcomes 11%
• Adverse Consequences 11%
• Anonymized 11%
• Previous Treatment 11%
• Mortality Rate 11%
• Machine Learning 11%
• Electronic Health Records 11%
• Mortality Benefit 11%
• Anticoagulation 11%
• Prolonged Hospital Stay 11%
• Fixed-dose Combination 11%
• Overweight or Obesity 11%
• Major Bleeding 11%
• Feature-rich 11%
• Non-majors 11%
• Rivaroxaban 11%
• Tertiary Care Setting 11%
• Structured Query 11%
• Anonymized Dataset 11%
• Needs Validation 11%

Pharmacology, Toxicology and Pharmaceutical Science

• Direct Oral Anticoagulant 100%
• Morbid Obesity 44%
• All Cause Mortality 22%
• Apixaban 22%
• Brain Ischemia 22%
• Bleeding 11%
• Rivaroxaban 11%

Biochemistry, Genetics and Molecular Biology

• Body Weight 100%
• All Cause Mortality 33%
• Electronic Health Record 16%
• Anticoagulation 16%
• Drug Dose Regimen 16%
• Rivaroxaban 16%